Abstract
Objectives Considering three viral transmission routes: fomite contact, aerial transmission by droplets, and aerial transmission by aerosols, the aerial routes have been the focus of debate about the relative role of droplets and aerosols in SARS-CoV-2 infection. We seek to quantify infection risk in an enclosed space via short-range airborne transmission from droplets and long-range risk from aerosols toward focusing public health measures.
Methods Data from three published studies were analyzed to predict relative exposure at distances of 1 m and farther, mediated by droplet size divided into two bins: larger than 8 µm and smaller than 75 µm (medium droplets) and smaller than 8 µm (small droplets or aerosols). The results at 1 m from an infectious individual were treated as a boundary condition to model infection risk at greater distance. At all distances, infection risk was treated as the sum of exposure to small and medium droplets. It was assumed that number of virions is proportional to droplet volume.
Results The largest infection risk (as exposure to droplet volume) came from medium droplets, close to the infectious individual out to approximately 1 m. Farther away, the largest risk was due to aerosols. For one model, medium droplet exposure disappeared at 1.8 m.
Conclusions Policy concerning social distancing for meaningful infection reduction relies on droplet exposure as a function of distance, yet within this construct droplet size determines respiratory deposition. This two-fold distance effect can be used to evaluate additional measures such as plexiglass barriers and masking.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Science Foundation Grant DMS 2054199 Riksbankens Jubileumsfond (Swedish Foundation for the Social Sciences and Humanities) program on Science and Proven Experience National Institutes of Health Grant R01 AG052550-01A1
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All data produced in the present work are contained in the manuscript
